Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15906031rdf:typepubmed:Citationlld:pubmed
pubmed-article:15906031lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0280100lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0080125lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C1832064lld:lifeskim
pubmed-article:15906031lifeskim:mentionsumls-concept:C0908892lld:lifeskim
pubmed-article:15906031pubmed:issue4lld:pubmed
pubmed-article:15906031pubmed:dateCreated2005-7-27lld:pubmed
pubmed-article:15906031pubmed:abstractTextRPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The purpose of this study was to evaluate the safety and pharmacokinetics of RPI.4610 in combination with carboplatin and paclitaxel in patients with advanced solid tumors.lld:pubmed
pubmed-article:15906031pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:languageenglld:pubmed
pubmed-article:15906031pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:citationSubsetIMlld:pubmed
pubmed-article:15906031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15906031pubmed:statusMEDLINElld:pubmed
pubmed-article:15906031pubmed:monthOctlld:pubmed
pubmed-article:15906031pubmed:issn0344-5704lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:KobayashiHiro...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:EckhardtS...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:HoldenScott...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:SandlerAlan...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:RothenbergMac...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:LockridgeJenn...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:WolinMauriceMlld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:CooperWendyWlld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:O'BryantCindy...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:UsmanNassimNlld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:AitchisonRoge...lld:pubmed
pubmed-article:15906031pubmed:authorpubmed-author:BascheMichele...lld:pubmed
pubmed-article:15906031pubmed:issnTypePrintlld:pubmed
pubmed-article:15906031pubmed:volume56lld:pubmed
pubmed-article:15906031pubmed:ownerNLMlld:pubmed
pubmed-article:15906031pubmed:authorsCompleteYlld:pubmed
pubmed-article:15906031pubmed:pagination329-36lld:pubmed
pubmed-article:15906031pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:meshHeadingpubmed-meshheading:15906031...lld:pubmed
pubmed-article:15906031pubmed:year2005lld:pubmed
pubmed-article:15906031pubmed:articleTitleSafety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.lld:pubmed
pubmed-article:15906031pubmed:affiliationVanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232-6307, USA.lld:pubmed
pubmed-article:15906031pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15906031pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15906031pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15906031pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15906031pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15906031lld:pubmed